GenXPro
Private Company
Total funding raised: $17.5M
Overview
GenXPro is a privately held, revenue-generating service and platform company based in Frankfurt, Germany, that has been a pioneer in NGS and bioinformatics since 2005. The company's core value proposition lies in its sensitive, low-bias sample preparation kits and full-service offerings, powered by its proprietary TrueQuant UMI technology, which ensures highly accurate quantitative genomics data. It serves diverse markets including academic research, pharmaceutical R&D (particularly in liquid biopsy and precision medicine), and agricultural biotechnology (SMART Breeding). With a strong foundation in molecular biology and bioinformatics, GenXPro is positioned as a specialized provider bridging the gap between complex biological samples and actionable genomic insights.
Technology Platform
Proprietary NGS sample preparation kits and bioinformatics pipelines, centered on the patented TrueQuant technology which uses Unique Molecular Identifiers (UMIs) to eliminate PCR bias and enable highly accurate quantitative genomics.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
GenXPro competes in a crowded field of NGS service providers, ranging from large-cap instrument manufacturers (e.g., Illumina, Thermo Fisher) offering services to large CROs (e.g., Eurofins, Charles River) and numerous niche bioinformatics firms. Its primary competitive differentiation is its focus on low-bias, quantitative data from minute samples via its proprietary TrueQuant UMI technology, positioning it as a specialist for demanding applications like liquid biopsy and low-input transcriptomics.